Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Sadoff

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
Infection and Immunity|September 1, 1996
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaJ A Tine, D E Lanar, D M Smith, et al.
Critical Care Medicine|July 1, 1997
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator GroupS M Opal, C J Fisher, J F Dhainaut, et al.
The Journal of Infectious Diseases|June 2, 1998
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaC F Ockenhouse, P F Sun, D E Lanar, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
Infection and Immunity|September 1, 1996
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaJ A Tine, D E Lanar, D M Smith, et al.
Critical Care Medicine|July 1, 1997
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator GroupS M Opal, C J Fisher, J F Dhainaut, et al.
The Journal of Infectious Diseases|June 2, 1998
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaC F Ockenhouse, P F Sun, D E Lanar, et al.
Pageof 12